- Home
- GTX vs MIRM Comparison
GTX vs MIRM Comparison
Compare GTX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTX
- MIRM
- Stock Information
- Founded
- GTX 2018
- MIRM 2018
- Country
- GTX Switzerland
- MIRM United States
- Employees
- GTX N/A
- MIRM N/A
- Industry
- GTX Auto Parts:O.E.M.
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- GTX Consumer Discretionary
- MIRM Health Care
- Exchange
- GTX Nasdaq
- MIRM Nasdaq
- Market Cap
- GTX 2.0B
- MIRM 2.1B
- IPO Year
- GTX N/A
- MIRM 2019
- Fundamental
- Price
- GTX $9.64
- MIRM $50.42
- Analyst Decision
- GTX Strong Buy
- MIRM Strong Buy
- Analyst Count
- GTX 1
- MIRM 11
- Target Price
- GTX $12.00
- MIRM $57.00
- AVG Volume (30 Days)
- GTX 741.6K
- MIRM 527.8K
- Earning Date
- GTX 02-13-2025
- MIRM 02-26-2025
- Dividend Yield
- GTX 0.63%
- MIRM N/A
- EPS Growth
- GTX N/A
- MIRM N/A
- EPS
- GTX 1.01
- MIRM N/A
- Revenue
- GTX $3,576,000,000.00
- MIRM $307,028,000.00
- Revenue This Year
- GTX N/A
- MIRM $82.63
- Revenue Next Year
- GTX $3.10
- MIRM $26.43
- P/E Ratio
- GTX $9.48
- MIRM N/A
- Revenue Growth
- GTX N/A
- MIRM 112.14
- 52 Week Low
- GTX $7.13
- MIRM $23.14
- 52 Week High
- GTX $10.16
- MIRM $50.34
- Technical
- Relative Strength Index (RSI)
- GTX 58.02
- MIRM 68.76
- Support Level
- GTX $9.13
- MIRM $47.55
- Resistance Level
- GTX $9.85
- MIRM $50.00
- Average True Range (ATR)
- GTX 0.25
- MIRM 1.75
- MACD
- GTX -0.01
- MIRM 0.25
- Stochastic Oscillator
- GTX 71.03
- MIRM 97.90
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.